MBX Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $2.50B
- P/E (TTM)
- –
- Dividend yield
- –
About MBX Biosciences
Pharmaceutical Preparations, SIC 2834
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes precision peptide therapies to treat endocrine and metabolic disorders. The company utilizes its proprietary Precision Endocrine Peptide platform to engineer drug candidates with extended action profiles and less frequent administration. Its pipeline includes canvuparatide, a parathyroid hormone peptide prodrug for chronic hypoparathyroidism; MBX 4291, a GLP-1 and GIP receptor co-agonist prodrug evaluated for obesity; and imapextide, a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia. These investigational therapies serve patients suffering from hormonal deficiencies and metabolic conditions.
The company is incorporated in Delaware and maintains its principal executive offices in Carmel, Indiana. Its facilities include administrative and laboratory spaces in Carmel, Indiana, as well as additional space in Burlington, Massachusetts. MBX Biosciences conducts clinical development and research programs within the United States. The organization operates without commercial product revenue.
Summary of the business section of MBX Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MBX Biosciences, Inc.
- Headquarters
- Carmel, IN
- Address
- 11711 N. Meridian Street, Suite 300 46032
- Phone
- (317) 989-3100
- Website
- mbxbio.com
- Employees
- 63, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Indianapolis, Indiana
Stock & identifiers
- Ticker
- MBX
- Exchange
- Nasdaq
- IPO date
- Sep 13, 2024
- Shares outstanding
- 48M, Aug 3, 2026
- Public float
- $237.33M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1776111
- CUSIP
- 55287L101
- ISIN
- US55287L1017
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven L. Hoerter | President and CEO, Director | 102,938 |
| P. Kent Hawryluk | President & CEO, Director | 1,214,444 |
| Salomon Azoulay | Chief Medical Officer | 14,399 |
| John W. Smither | Chief Financial Officer | 28,000 |
| Richard Bartram | Chief Financial Officer | 15,000 |
| Patrick J. Heron | Director | 3,927,774 |
| Laurie Stelzer | Director | – |
| Ora H. Pescovitz | Director | 24,329 |
| Tiba Aynechi | Director | 1,386,335 |
| Steven Ryder | Director | – |
| Edward T. Mathers | Director | 3,614,486 |
| James M. Cornelius | Director | 102,082 |
| Carl L. Gordon | Director | 747,887 |
| Advisors Llc Orbimed | Director | 3,812,215 |
| Capital GP VII LLC OrbiMed | Director | – |
| Genesis GP LLC OrbiMed | Director | 3,255,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 63 full-time employees, of which thirteen have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 10, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |